Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Sybil Williams

1PUBLICATIONS

25CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Oct 15, 2025

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková

Pageof 1

Frequent Collaborators

1 joint publications

Franziska Siegel

1 joint publications

Stephan Siegel

1 joint publications

Kristýna Kotýnková

1 joint publications

Gizem Karsli Uzunbas

1 joint publications

Daniel Korr

1 joint publications

Haruna Tomono

1 joint publications

Sawyer Andersen

1 joint publications

Daniel Denney

1 joint publications

Markus Berger

1 joint publications

Volker K Schulze

Frequent Collaborators

1 joint publications

Franziska Siegel

1 joint publications

Stephan Siegel

1 joint publications

Kristýna Kotýnková

1 joint publications

Gizem Karsli Uzunbas

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos